Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.56 |
| ▸ | GAK | O14976 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5472215 | 0.93 | NOS1 (0.56) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5469941 | 0.92 | NOS1 (0.56) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5461357 | 0.91 | NOS1 (0.54) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5459283 | 0.89 | NOS1 (0.54) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5470451 | 0.89 | NOS1 (0.59) | NOS1GAKNEK2MAP4K1FYN | |
| SCHEMBL5464257 | 0.88 | NOS1 (0.54) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5466065 | 0.88 | NOS1 (0.52) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5461863 | 0.85 | NOS1 (0.55) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5466207 | 0.85 | NOS1 (0.55) | NOS1GAKSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5459267 | 0.85 | NOS1 (0.54) | NOS1GAKSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | claimed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | claimed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | NOS1 107/4885GAK 2048/4885SLC6A2 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.